HomeCompareSHJBF vs DGRO

SHJBF vs DGRO: Dividend Comparison 2026

SHJBF yields 66.67% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHJBF wins by $1.9K in total portfolio value
10 years
SHJBF
SHJBF
● Live price
66.67%
Share price
$3.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$11.08
Full SHJBF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — SHJBF vs DGRO

📍 SHJBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHJBFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHJBF + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHJBF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHJBF
Annual income on $10K today (after 15% tax)
$5,666.67/yr
After 10yr DRIP, annual income (after tax)
$9.42/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, DGRO beats the other by $194.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHJBF + DGRO for your $10,000?

SHJBF: 50%DGRO: 50%
100% DGRO50/50100% SHJBF
Portfolio after 10yr
$32.5K
Annual income
$125.52/yr
Blended yield
0.39%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHJBF buys
0
DGRO buys
0
No recent congressional trades found for SHJBF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHJBFDGRO
Forward yield66.67%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$33.5K$31.6K
Annual income after 10y$11.08$239.96
Total dividends collected$8.1K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SHJBF vs DGRO ($10,000, DRIP)

YearSHJBF PortfolioSHJBF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$14,033$3,333.33$11,293$213.22+$2.7KSHJBF
2$17,202$2,185.88$12,730$217.32+$4.5KSHJBF
3$19,658$1,252.04$14,326$221.10+$5.3KSHJBF
4$21,702$668.61$16,098$224.56+$5.6KSHJBF
5$23,566$344.93$18,064$227.74+$5.5KSHJBF
6$25,391$175.03$20,246$230.65+$5.1KSHJBF
7$27,257$88.12$22,666$233.30+$4.6KSHJBF
8$29,209$44.20$25,349$235.73+$3.9KSHJBF
9$31,276$22.14$28,325$237.94+$3.0KSHJBF
10$33,476$11.08$31,624$239.96+$1.9KSHJBF

SHJBF vs DGRO: Complete Analysis 2026

SHJBFStock

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Full SHJBF Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this SHJBF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHJBF vs SCHDSHJBF vs JEPISHJBF vs OSHJBF vs KOSHJBF vs MAINSHJBF vs VIGSHJBF vs NOBLSHJBF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.